TRYVIO

This brand name is authorized in United States

Active ingredients

The drug TRYVIO contains one active pharmaceutical ingredient (API):

1 Aprocitentan UNII MZI81HV01P - APROCITENTAN

Endothelin (ET)-1, via its receptors (ETA and ETB), mediates a variety of effects such as vasoconstriction, fibrosis, cell proliferation, and inflammation and is upregulated in hypertension. Aprocitentan is a dual ERA that inhibits the binding of ET-1 to ETA and ETB receptors and hence the effects mediated by these receptors. Read about Aprocitentan

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TRYVIO Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C02KN01		C Cardiovascular system → C02 Antihypertensives → C02K Other antihypertensives → C02KN Other antihypertensives
Discover more medicines within C02KN01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: US	FDA, National Drug Code	Identifier(s): 80491-125